In silico model-based inference: an emerging approach for inverse problems in engineering better medicines.

Identifying the network of biochemical interactions that underpin disease pathophysiology is a key hurdle in drug discovery. While many components involved in these biological processes are identified, how components organize differently in health and disease remains unclear. In chemical engineering, mechanistic modeling provides a quantitative framework to capture our understanding of a reactive system and test this knowledge against data. Here, we describe an emerging approach to test this knowledge against data that leverages concepts from probability, Bayesian statistics, and chemical kinetics by focusing on two related inverse problems. The first problem is to identify the causal structure of the reaction network, given uncertainty as to how the reactive components interact. The second problem is to identify the values of the model parameters, when a network is known a priori.

[1]  Stacey D. Finley,et al.  Inferring relevant control mechanisms for interleukin‐12 signaling in naïve CD4+ T cells , 2011, Immunology and cell biology.

[2]  B. Hemmings,et al.  PI3K-PKB/Akt pathway. , 2012, Cold Spring Harbor perspectives in biology.

[3]  Jonathan R. Karr,et al.  A Whole-Cell Computational Model Predicts Phenotype from Genotype , 2012, Cell.

[4]  G. Lahav,et al.  Encoding and Decoding Cellular Information through Signaling Dynamics , 2013, Cell.

[5]  Lillian L. Siu,et al.  Preclinical development of molecular-targeted agents for cancer , 2011, Nature Reviews Clinical Oncology.

[6]  Andrew Thomas,et al.  The BUGS project: Evolution, critique and future directions , 2009, Statistics in medicine.

[7]  Stefano Severi,et al.  Comprehensive Analyses of Ventricular Myocyte Models Identify Targets Exhibiting Favorable Rate Dependence , 2014, PLoS Comput. Biol..

[8]  David J Klinke,et al.  In silico model‐based inference: A contemporary approach for hypothesis testing in network biology , 2014, Biotechnology progress.

[9]  Doraiswami Ramkrishna,et al.  Mathematics in Chemical Engineering: A 50 Year Introspection (Journal Review) , 2004 .

[10]  B. Hemmings,et al.  The PI3K-PKB/Akt pathway. , 2015, Cold Spring Harbor perspectives in biology.

[11]  K Gadkar,et al.  The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non‐obese diabetic mouse , 2010, Clinical and experimental immunology.

[12]  D. Klinke,et al.  Interlocked positive and negative feedback network motifs regulate β-catenin activity in the adherens junction pathway , 2015, Molecular biology of the cell.

[13]  David J. Klinke,et al.  An empirical Bayesian approach for model-based inference of cellular signaling networks , 2009, BMC Bioinformatics.

[14]  Steffen Klamt,et al.  Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling , 2015, PLoS Comput. Biol..

[15]  Julio Saez-Rodriguez,et al.  Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks , 2012, BMC Systems Biology.

[16]  K. Janes An analysis of critical factors for quantitative immunoblotting , 2015, Science Signaling.

[17]  Jeremy L. Muhlich,et al.  Properties of cell death models calibrated and compared using Bayesian approaches , 2013, Molecular systems biology.

[18]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[19]  L. Gossage,et al.  Targeting Multiple Kinase Pathways: A Change In Paradigm , 2010, Clinical Cancer Research.

[20]  David J. Klinke,et al.  Quantifying Crosstalk Among Interferon-γ, Interleukin-12, and Tumor Necrosis Factor Signaling Pathways Within a TH1 Cell Model , 2012, Science Signaling.

[21]  P Vicini,et al.  Systems Pharmacology for Drug Discovery and Development: Paradigm Shift or Flash in the Pan? , 2013, Clinical pharmacology and therapeutics.

[22]  Mark A. Girolami,et al.  BioBayes: A software package for Bayesian inference in systems biology , 2008, Bioinform..

[23]  M. Girolami,et al.  Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species , 2010, Science Signaling.

[24]  Darren J. Wilkinson,et al.  CaliBayes and BASIS: integrated tools for the calibration, simulation and storage of biological simulation models , 2010, Briefings Bioinform..

[25]  C. Stokes,et al.  Preexisting Autoantibodies Predict Efficacy of Oral Insulin to Cure Autoimmune Diabetes in Combination With Anti-CD3 , 2012, Diabetes.

[26]  R. Plenge,et al.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.

[27]  Fabian J Theis,et al.  High-dimensional Bayesian parameter estimation: case study for a model of JAK2/STAT5 signaling. , 2013, Mathematical biosciences.

[28]  Linda J. Broadbelt,et al.  Construction of a mechanistic model of Fischer–Tropsch synthesis on Ni(1 1 1) and Co(0 0 0 1) surfaces , 1999 .

[29]  Thomas Thorne,et al.  Model selection in systems and synthetic biology. , 2013, Current opinion in biotechnology.

[30]  F. Baran-Marszak,et al.  STAT3 inhibitors for cancer therapy , 2013, JAK-STAT.

[31]  J. Pearl Causality: Models, Reasoning and Inference , 2000 .

[32]  Stacey D. Finley,et al.  Timescale analysis of rule‐based biochemical reaction networks , 2012, Biotechnology progress.

[33]  Ulrik B. Nielsen,et al.  Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.

[34]  Eduardo D. Sontag,et al.  Inferring dynamic architecture of cellular networks using time series of gene expression, protein and metabolite data , 2004, Bioinform..

[35]  Ioannis G. Kevrekidis,et al.  Matrices are forever: On applied mathematics and computing in chemical engineering , 1995 .

[36]  K. Bischoff,et al.  The delplot technique: a new method for reaction pathway analysis , 1990 .

[37]  M R Birtwistle,et al.  Mechanistic Vs. Empirical Network Models of Drug Action , 2013, CPT: pharmacometrics & systems pharmacology.

[38]  D. Ramkrishna,et al.  2 Mathematics in Chemical Engineering , 2009 .

[39]  X. Tian,et al.  JAK-STAT3 and somatic cell reprogramming , 2013, JAK-STAT.

[40]  E. Jaynes Probability theory : the logic of science , 2003 .

[41]  Melvin E. Andersen,et al.  In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[42]  E. Estey,et al.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. , 2010, Blood.

[43]  Matthias von Herrath,et al.  Virtual Optimization of Nasal Insulin Therapy Predicts Immunization Frequency to Be Crucial for Diabetes Protection , 2010, Diabetes.

[44]  Gordon Ellis,et al.  Grand challenges for engineering , 2009, IEEE Engineering Management Review.

[45]  Birgit Schoeberl,et al.  An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. , 2010, Cancer research.